PDS Biotechnology Corp (PDSB) research
PDS Biotechnology Corp- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.75
- As of
PDS Biotechnology Corp (PDSB): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-22.
As of . Source: SEC EDGAR filings for PDSB. Method and limitations.
Share the PDSB intelligence card
See the full PDSB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PDSB on one page. Preview it with sample data, then open it live with a free account.
Preview the PDSB dossierActive signals for PDSB
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 94% of PDSB (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 35.7%, EPS $-0.18 vs $-0.1326 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 11.8% - EPS $-0.21 vs $-0.238 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 15.0% - EPS $-0.13 vs $-0.153 estimate
- mediumEARNINGS_BEAT
Beat consensus by 11.8% - EPS $-0.21 vs $-0.238 estimate
FREE, NO ACCOUNT
Every signal on PDSB, as it fires
You are seeing 5 of 8 signals recorded on PDSB since 2026-06-02.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PDSB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 70465T107 · 2026Q2 | $285K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 70465T107 · 2026Q2 | $222K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PDSB
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
PDSB against its peers
PDSB's return on equity of -372.9% ranks in the 12th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | PDSB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 100000 | n/a | 15 |
| Operating margin | n/a | -8021.4% | n/a | 11 |
| Net margin | n/a | -8375.6% | n/a | 11 |
| Return on equity | -372.9% | -106.4% | 12 | 20 |
Peers (24): INMB, EXOZ, IBIO, CNTB, IMA, ANVS, MREO, BOLD, ACET, XLO, ELOX, SER, AURX, HYPD, ELTX, INKT, RNTX, ATHE, IBO, TIL, GUTS, XBIT, HRTX, LITS. Left out: HYFT (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PDSB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more PDSB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to PDSBand get the insider, 13F, options, and confluence read in one view.